Patient P-02559
Synthetic patientMETA-24 · Day 141 · 25–34 · F · baseline S18Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
86%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S18
- Day 21 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 65 SC-12 recommended — Supportive Compound SC-12
- Day 66 Patient accepted — Started SC-12 in the companion
- Day 72 No meaningful change — Supportive Compound SC-12
- Day 83 ME-01 recommended — Monitoring Escalation ME-01
- Day 84 Patient accepted — Started ME-01 in the companion
- Day 87 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 21.
Primary contributors, last 14 days
- Toxicity+14
- Inflammatory activity+12
- Nutritional resilience-4
- Treatment adherence-3
What helped?
- Supportive Compound SC-12Day 65Result: no meaningful change
- Monitoring Escalation ME-01Day 83Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
90%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable41 min
worsening · -2.6 vs previous 14 d
Sleep duration
Wearable7.1 h
stable · -0.1 vs previous 14 d
Energy level
Daily log2.7/10
stable · +0.1 vs previous 14 d
Steps
Wearable3,739
stable · -52 vs previous 14 d
GI burden
Companion59.5/100
improving · -6.3 vs previous 14 d
Adherence
Companion40.7 %
worsening · -6.6 vs previous 14 d
Sleep quality
Wearable52.3/100
stable · +0.7 vs previous 14 d
Glucose, CGM daily mean
CGM136 mg/dL
stable · -2.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 26 from the failing basin, 64 from restoration.
Would help
- GI-04 GI Support Protocol75% improved among 65 similar · onset 8 d · confidence 89%
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 74%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 74%
- More proteinGI -5.7 next day on high-intake days · n 17
Would not help
- SC-12 Supportive Compoundalready tried, no meaningful change
- Keep fibre lowGI +5.9 next day on high-intake days · n 13
- Keep fat lowGI +5.6 next day on high-intake days · n 19
- Keep histamine lowGI +5.4 next day on high-intake days · n 17
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Insoluble fibre+5.9detractor · 95%
- Protein-5.7supporter · 95%
- Dietary fat load+5.6detractor · 95%
- Histamine load+5.4detractor · 95%
- Ultra-processed food+3detractor · 66%
- Alcohol+1.5no signal · 25%
- Simple carbohydrates-1.2no signal · 25%
- Caffeine-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- Drug metabolism and exposure ↑20
- BloodToxicity index 57
- Autonomic recovery ↓20
- Wearable3,739 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.2 · butyrate capacity 26/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 7.2 h
- Steps
- 5,496
- Resting HR
- 66 bpm
Daily log: GI score 60, nutritional resilience 37, adherence 41.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02483 | 20% | S06 | BR-03 | no change | 64 |
| P-02087 | 18% | S01 | BR-03 | no change | 40 |
| P-02308 | 18% | S13 | BR-03 | no change | 27 |
| P-02025 | 34% | S15 | CR-01 | improved | 61 |
| P-02151 | 32% | S04 | CR-01 | improved | 49 |
| P-02054 | 31% | S01 | CR-01 | improved | 57 |
| P-02009 | 28% | S08 | CR-01 | improved | 64 |
| P-02154 | 28% | S16 | CR-01 | improved | 57 |
| P-02233 | 25% | S16 | CR-01 | improved | 66 |
| P-02395 | 20% | S12 | DT-01 | improved | 57 |
| P-02274 | 19% | S15 | DT-01 | improved | 50 |
| P-02339 | 19% | S03 | DT-01 | improved | 50 |